MAY 30, 2014 10:30 AM PDT
Universal Definition of MI
Presented at the Clinical Diagnostics and Research Virtual Event
54 50 1898

Speakers:
  • Director, Scientific Affairs Cardiac, Roche Diagnostics Corporation
    Biography
      Hans-Juergen Loyda, Ph.D., MBA, is Director of Clinical Development and Education of Medical and Scientific Affairs at Roche Diagnostics in Indianapolis. He holds a Bachelor of Science in Biology, a Doctorate in Zoology from the Rheinisch-Friedrichs-Wilhelms University in Bonn/Germany and a Master of Business Administration from the Indiana Wesleyan University. He has been with Roche Diagnostics for 28 years with extensive experience in sales and marketing. The last 8 years he has focused on developing relevant and compelling clinical evidence for cardiac biomarker in Medical & Scientific Affairs. For this area he is also scientific resource internally and externally.

    Abstract:
    The program "The Universal Definition of MI & Troponin, Clearing the confusion" is intended to review the recently released Third Universal Definition of Myocardial Infarction and aims to familiarize clinicians and laboratory health care providers with the implications for current practice.

    The focus will be on understanding the use of troponin in the Clinical Setting and my discussions will include:
    • The identification of pathological characteristics of myocardial ischemia and infarction,
    • The classification framework created by the 2007 Universal Definition of MI,
    • The biomarker preference and endorsement of cardiac troponins as preferred biomarker for each category of MI emphasizing that an increased troponin concentration is defined as a value exceeding the 99th percentile of a normal reference population, and
    • The differentiation of acute and chronic cTn elevations.

    Show Resources
    Loading Comments...
    Show Resources